5-Aminolevulinic
acid (ALA) is an imperative compound that has
been widely applied in the agricultural and medical fields. The ALA
synthesis in Escherichia coli via the
C4 pathway depends on ALA synthase (ALAS) and releases CO2 in a single-step reaction. However, enhancement of the ALA production
by increasing the protein’s quality and quantity with simultaneous
CO2 reduction has never been reported. In this study, the
expression and activity of ALAS were improved by employing chaperone
and rare tRNAs. Moreover, the pdxY gene was introduced
for pyridoxal phosphate (PLP) regeneration, a cofactor for ALAS, and
significantly increased ALA production to 14.3 g/L through stepwise
strain engineering with an optimal feeding strategy. The leading excess
CO2 emission was further reused as a second carbon source
for cell growth and ALA synthesis by cloning the ribulose-1,5-bisphosphate
carboxylase/oxygenase (RuBisCo) and phosphoribulokinase (Prk) in E. coli. As a result, the co-application of RuBisCo,
Prk, and ALAS reduced CO2 emission by 53.8% in combination
with pdxY and pRARE. Finally, the crude ALA was demonstrated
and applied in the antibacterial photodynamic therapy (aPDT) against
three different pathogens. The robust strain, RSSA-BY with a lower
carbon footprint, achieved the highest cell growth and efficient ALA
production for aPDT for the first time, providing a vital and green
bioprocess toward an advanced and sustainable future.